Memorial Sloan Kettering Cancer Center shared a post on X:
“The FDA has approved daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s Eileen M O’Reilly led the phase 3 trial at MSK showing it doubled median survival compared with chemotherapy.
‘To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease.’
Learn more about the approval and what it could mean for patients.”
Other articles about Memorial Sloan Kettering Cancer Center on OncoDaily.